Value
8.0/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.3 |
| Fwd P/E | 6.2 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 20.9x
- ▸PEG: 0.13
- ▸Attractively valued
GERN · Why this verdict
Why Geron (GERN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock sits roughly 157% below the consensus analyst price target, and the risk/reward ratio of roughly 22-to-1 reflects an unusually wide gap between the current price of $1.15 and the $2.96 fair value estimate. Price targets | The share price moves toward $2.96 over 12 months as clinical or commercial milestones narrow the discount to analyst fair value. | →Stable |
| CounterA ratio of 22-to-1 in favor of upside in a sub-$1 billion market cap biotechnology company almost always reflects the market discounting a high probability of dilution or clinical failure; the large upside and large risk/reward ratio together can be a sign of distress, not opportunity. | ||
At a market capitalization of $0.74 billion, the company falls below the $1 billion minimum for the investable universe, which limits institutional participation, reduces liquidity, and increases the risk of sharp price dislocations on any adverse news. Warnings | Market capitalization rises above $1.0 billion — the minimum threshold — sustained for at least 4 consecutive weeks, making the stock eligible for the investable universe. | →Stable |
| CounterA sub-$1 billion market cap reflects the current price, not the forward value; if a clinical or commercial catalyst materializes, the market cap could cross the threshold quickly without any change in the fundamental business trajectory. | ||
Free cash flow is negative at 47% of revenue — meaning nearly half of every dollar of revenue is consumed by the cash burn — raising the risk that the company will need to return to capital markets before the current strategy reaches cash-flow breakeven. Quality breakdown | Cash burn narrows to less than 20% of revenue for 2 consecutive quarters, indicating that the rate of cash consumption is decelerating toward breakeven. | →Stable |
| CounterTwo recent reported quarters ended with positive earnings surprises of roughly 53% and 24%, suggesting the company is beating its own cost guidance; if burn continues to come in better than expected, the runway may be longer than the headline burn rate implies. | ||
The put-to-call ratio sits at 5.00 — an extreme reading — and short interest stands at 11% of float, indicating that a significant portion of the market is positioned for the stock to decline further. Risk breakdown | The put-to-call ratio compresses below 2.0 and short interest falls below 7% of float, signaling that the extreme bearish positioning has unwound. | →Stable |
| CounterA put-to-call ratio of 5.00 in a small biotechnology name can be dominated by a single large hedge trade rather than broad market consensus; thin options volume can make the ratio a poor signal of institutional conviction. | ||
The stock sits roughly 157% below the consensus analyst price target, and the risk/reward ratio of roughly 22-to-1 reflects an unusually wide gap between the current price of $1.15 and the $2.96 fair value estimate.
→StablePrice targets
- Expectation
- The share price moves toward $2.96 over 12 months as clinical or commercial milestones narrow the discount to analyst fair value.
CounterA ratio of 22-to-1 in favor of upside in a sub-$1 billion market cap biotechnology company almost always reflects the market discounting a high probability of dilution or clinical failure; the large upside and large risk/reward ratio together can be a sign of distress, not opportunity.
At a market capitalization of $0.74 billion, the company falls below the $1 billion minimum for the investable universe, which limits institutional participation, reduces liquidity, and increases the risk of sharp price dislocations on any adverse news.
→StableWarnings
- Expectation
- Market capitalization rises above $1.0 billion — the minimum threshold — sustained for at least 4 consecutive weeks, making the stock eligible for the investable universe.
CounterA sub-$1 billion market cap reflects the current price, not the forward value; if a clinical or commercial catalyst materializes, the market cap could cross the threshold quickly without any change in the fundamental business trajectory.
Free cash flow is negative at 47% of revenue — meaning nearly half of every dollar of revenue is consumed by the cash burn — raising the risk that the company will need to return to capital markets before the current strategy reaches cash-flow breakeven.
→StableQuality breakdown
- Expectation
- Cash burn narrows to less than 20% of revenue for 2 consecutive quarters, indicating that the rate of cash consumption is decelerating toward breakeven.
CounterTwo recent reported quarters ended with positive earnings surprises of roughly 53% and 24%, suggesting the company is beating its own cost guidance; if burn continues to come in better than expected, the runway may be longer than the headline burn rate implies.
The put-to-call ratio sits at 5.00 — an extreme reading — and short interest stands at 11% of float, indicating that a significant portion of the market is positioned for the stock to decline further.
→StableRisk breakdown
- Expectation
- The put-to-call ratio compresses below 2.0 and short interest falls below 7% of float, signaling that the extreme bearish positioning has unwound.
CounterA put-to-call ratio of 5.00 in a small biotechnology name can be dominated by a single large hedge trade rather than broad market consensus; thin options volume can make the ratio a poor signal of institutional conviction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Geron offers 157% upside to the analyst consensus price target with 31% revenue growth and two recent earnings beats, but the company falls below the minimum investable market cap at $0.74 billion, burns cash at 47% of revenue, and carries a put-to-call ratio of 5.00 — the asymmetry is extraordinary on paper, yet the business is too small and too speculative to meet the investability threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 8.2 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.2 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -47% of revenue
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 31% YoY
Momentum
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.7 |
| MACD | 6.8 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 1.3 |
- ▸Overbought bear rally (RSI 74)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -1.4%/30d — confirmed downtrend
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.8 |
- ▸Analyst upside: 150%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.1 |
| quality rank | 4.2 |
| growth rank | 6.1 |
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 2.8 |
| 52w position | 3.5 |
| gap | 5.0 |
Risk (lower is worse)
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.2 |
| days to cover | 3.9 |
| volatility | 0.0 |
| put call | 10.0 |
| beta | 9.4 |
| debt equity | 7.8 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- ASYMMETRY:7.8>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.6<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
7.83
Upside
+117.5%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 74
EdgeInst Constrain — Small cap ($0.9B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.6<4.5.
The strongest dimensions are Growth at 10.0, Value at 8.0, and Catalyst at 7.5; the weakest are Quality at 3.1, Technical at 3.3, and Momentum at 3.6. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 7.83 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extraordinary Upside Asymmetry
Trip ifConsensus analyst price target falls below $1.50, compressing implied upside to less than 30% from the current $1.15 price.
- P2Below Minimum Investable Threshold
Trip ifMarket capitalization rises above $1.0 billion sustained for 4 consecutive weeks, moving the stock into the investable universe.
- P3Cash Burn Limits Runway
Trip ifCash burn narrows to less than 20% of revenue for 2 consecutive quarters, indicating the burn rate is decelerating materially.
- P4Extreme Bearish Options Positioning
Trip ifPut-to-call ratio falls below 2.0 and short interest falls below 7% of float, indicating the extreme bearish positioning has unwound.